{"entity":{"id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Yizhong Pharmaceutical Co., Ltd., now recruiting.","summary":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT06752811 by Shanghai Yizhong Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-02-05 and due to reach its primary completion in 2027-07-01. Interventions recorded: paclitaxel polymeric micelles for injection, Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (albumin bound ).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06752811","url":"https://clinicaltrials.gov/study/NCT06752811"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06752811","phase":"3","setting":"A Multi-center, Randomized, Open, Parallel-group, Positive Drug-controlled Phase III Clinical Trial for Evaluating the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Plus Gemcitabine and Paclitaxel for Injection (Albumin-bound) Plus Gemcitabine for Injection in the First-line Treatment of Metastatic Pancreatic Cancer","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","enrolled":416,"outcomes":[]},"route":"/trials/nct06752811/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}